Seres Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seres Therapeutics, Inc. on June 17, 2016, regarding events occurring on June 15, 2016. The filing details the results of the Company's Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A total of 35,945,965 shares of common stock were present at the meeting, representing approximately 91% of outstanding shares as of the April 22, 2016 record date. The following proposals were approved:
- Item 1: Election of Directors
- Dennis A. Ausiello, M.D.: Elected with 29,428,188 votes FOR, 3,611,697 votes WITHHELD, and 2,906,080 Broker Non-Votes.
- Roger J. Pomerantz, M.D.: Elected with 31,177,517 votes FOR, 1,862,368 votes WITHHELD, and 2,906,080 Broker Non-Votes.
- Item 2: Ratification of Auditors
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2016.
- Votes: 35,927,811 FOR, 13,085 AGAINST, 5,069 ABSTAINED, and 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the official appointment of Dennis A. Ausiello, M.D. and Roger J. Pomerantz, M.D. as Class I directors serving until the 2019 Annual Meeting.
- Confirm the engagement of PricewaterhouseCoopers LLP for the 2016 fiscal year audit.
- Note the high level of shareholder participation (91%) at the Annual Meeting.